Mint Tower Capital Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

Mint Tower Capital Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26K	Hold	25,000	–	–	﹤0.01%	293
2025 Q4	$132K	Hold	25,000	–	–	0.02%	197
2025 Q3	$5K	Hold	25,000	–	–	﹤0.01%	190
2025 Q2	$7K	Hold	25,000	–	–	﹤0.01%	144
2025 Q1	$15K	Hold	25,000	–	–	0.01%	111
2024 Q4	$1K	Hold	25,000	–	–	﹤0.01%	143
2024 Q3	$1K	Hold	25,000	–	–	﹤0.01%	147
2024 Q2	$1K	Hold	25,000	–	–	﹤0.01%	137
2024 Q1	$1K	Hold	25,000	–	–	﹤0.01%	184
2023 Q4	$2K	Hold	25,000	–	–	﹤0.01%	165
2023 Q3	$1K	Hold	25,000	–	–	﹤0.01%	259
2023 Q2	$1K	Hold	25,000	–	–	﹤0.01%	246
2023 Q1	$1K	Hold	25,000	–	–	﹤0.01%	278
2022 Q4	$2K	Hold	25,000	–	–	﹤0.01%	349
2022 Q3	$3K	Hold	25,000	–	–	﹤0.01%	463
2022 Q2	$4K	Buy	+25,000	New	+$5.44K	﹤0.01%	401

Other funds holding ASBPW

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return

Mint Tower Capital Management's ASBPW Position: Q1 2026 in Review

Mint Tower Capital Management held its Aspire Biopharma Warrant (ASBPW) position steady in Q1 2026 at 25,000 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #293.

Mint Tower Capital Management first reported a position in ASBPW in Q2 2022 and has held it in 16 quarters since. The position peaked at $132K in Q4 2025. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

Mint Tower Capital Management held 25,000 shares of Aspire Biopharma Warrant worth $26K as of Q1 2026.
Mint Tower Capital Management left its Aspire Biopharma Warrant share count unchanged in Q1 2026.
Aspire Biopharma Warrant made up ﹤0.01% of Mint Tower Capital Management's portfolio in Q1 2026, its #293 holding.
Mint Tower Capital Management first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 16 quarters since.
Mint Tower Capital Management's Aspire Biopharma Warrant position peaked at $132K in Q4 2025.
29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on Mint Tower Capital Management's 13F filing for Q1 2026, filed 4 May 2026.